You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist
|
|---|---|
| Published in |
The Journal of Pharmacology and Experimental Therapeutics, April 2014
|
| DOI | 10.1124/jpet.114.213694 |
| Pubmed ID | |
| Authors |
Klaus Linz, Thomas Christoph, Thomas M. Tzschentke, Thomas Koch, Klaus Schiene, Michael Gautrois, Wolfgang Schröder, Babette Y. Kögel, Horst Beier, Werner Englberger, Stefan Schunk, Jean De Vry, Ulrich Jahnel, Stefanie Frosch |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 88 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 19% |
| Other | 11 | 13% |
| Student > Bachelor | 11 | 13% |
| Researcher | 11 | 13% |
| Student > Master | 6 | 7% |
| Other | 10 | 11% |
| Unknown | 22 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 20% |
| Medicine and Dentistry | 12 | 14% |
| Chemistry | 7 | 8% |
| Agricultural and Biological Sciences | 7 | 8% |
| Neuroscience | 6 | 7% |
| Other | 11 | 13% |
| Unknown | 27 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#1,265,900
of 25,837,817 outputs
Outputs from The Journal of Pharmacology and Experimental Therapeutics
#99
of 5,702 outputs
Outputs of similar age
#12,306
of 243,718 outputs
Outputs of similar age from The Journal of Pharmacology and Experimental Therapeutics
#2
of 48 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,702 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,718 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.